Prognostic relevance of cytogenetic abnormalities in primary myelofibrosis: Comparison of recent reports from Japan, the Mayo Clinic and MD Anderson Cancer Center

European Journal of Haematology

Volumn 83, Issue 4, 2009, Pages 290-291

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOSOME 13Q; CHROMOSOME 20Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CYTOGENETICS; EDITORIAL; GENE MUTATION; HUMAN; KARYOTYPE; MYELOID METAPLASIA; PRIORITY JOURNAL; SURVIVAL RATE; TRISOMY 8;

CHROMOSOME ABERRATIONS; JAPAN; PRIMARY MYELOFIBROSIS; PROGNOSIS; UNITED STATES;

EID: 70349147336     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01304.x     Document Type: Editorial

References (9)

1. Hussein K, Van Dyke DL, Tefferi A. Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur J Haematol 2009 82 : 329 338.
2. Hussein K, Huang J, Lasho T, et al. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol 2009 82 : 255 259.
3. Tam CS, Abruzzo LV, Lin KI, et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood 2009 113 : 4171 4178.
4. Hidaka T, Shide K, Shimoda H, et al. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan. Eur J Haematol 2009 83 : 328 333.
5. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001 113 : 763 771. (Pubitemid 32524401)
6. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009 113 : 2895 2901.
7. Tefferi A, Mesa RA, Pardanani A, et al. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol 2009 84 : 265 267.
8. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009 23 : 905 911.
9. Tefferi A. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J Cell Mol Med 2009 13 : 215 237.